COMMUNIQUÉS West-GlobeNewswire

Cannara to Host Investor Webcast on February 19th, 2026
12/02/2026
MONTREAL, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) ( TSXV: LOVE ) ( OTCQX: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
Athelas Home Expands AI Diagnostics to the Point of Care with FDA Clearance
12/02/2026
MOUNTAIN VIEW, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Athelas, a Commure company, today announced that the FDA cleared the CLIA-waived Athelas Home diagnostic device for use in point-of-care settings. The AI-powered [...]
Philips introduces InkSpace Imaging’s Snuggle™ flexible pediatric MRI coil for its 3.0T MR systems, helping to enhance imaging precision, efficiency and comfort
12/02/2026
February 12, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the availability of the InkSpace Imaging Snuggle™ pediatric body array coil for [...]
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer
12/02/2026
BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]
Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
12/02/2026
GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the [...]
Aardvark Therapeutics Announces Leadership Appointments
12/02/2026
SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate [...]
PsiThera to Participate in Piper Sandler Virtual Novel Targets in Immunology Symposium
12/02/2026
WATERTOWN, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PsiThera, Inc. today announced that Chief Executive Officer Eric Shaff, Founder and Chief Innovation Officer Woody Sherman, Ph.D., and Chief Scientific Officer Camil [...]
Vericel to Report Fourth-Quarter and Full-Year 2025 Financial Results on February 26, 2026
12/02/2026
CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report [...]
Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia
12/02/2026
- Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modulating properties, and the execution of high-value commercial [...]
Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices
12/02/2026
BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies, today highlighted new survey findings [...]
Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference
12/02/2026
NORWOOD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive [...]
Totus Medicines to Present Updated Phase 1 Clinical Data for TOS-358 at ESMO Targeted Anticancer Therapies Congress 2026
12/02/2026
Oral presentation to highlight updated Phase 1 monotherapy safety and efficacy data for TOS-358, a covalent PI3K a inhibitor Data will include efficacy and safety in heavily pretreated patients with PI3K a -mutant [...]
Trethera to Highlight Clinical Momentum and Indication Expansion at Biocom Global Partnering & Investor Conference
12/02/2026
LOS ANGELES, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announces an upcoming [...]
ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS
12/02/2026
Based in New Jersey (USA), to lead ORYZON’s CNS clinical development MADRID and CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage [...]
OneMedNet Reports Record 2025 Bookings of $2.79 Million, Surpassing Prior Year by More Than 4.1X and Accelerating Subscription Transition
12/02/2026
MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leader in AI-powered Real-World Data (RWD), today announced record bookings in 2025 [...]
ImmuneSensor Therapeutics Doses First Patient with Aicardi Goutières Syndrome (AGS) in Phase 1b Clinical Study of cGAS inhibitor, IMSB301
12/02/2026
Trial expansion into AGS and other Type 1 interferonopathies follows successful Phase 1a clinical trial of IMSB301 in healthy volunteers, which demonstrated a well-tolerated safety profile and dose-dependent exposure [...]
Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference
12/02/2026
SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today [...]
Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update
12/02/2026
- The first 4 Patients enrolled into Cohort 1 of the BB-301 Phase 1b/2a treatment study have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the 12-month [...]
Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026
12/02/2026
ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial [...]

Pages